Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

Publisher： Karger

E-ISSN： 1662-6575|2|3|194-202

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.2, Iss.3, 2009-10, pp. : 194-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Radioimmunotherapy of B-cell lymphoma with radiolabelled anti-CD20 monoclonal antibodies

By Dillman R.  

Clinical and Experimental Medicine, Vol. 6, Iss. 1, 2006-03 ,pp. : 1-12

Springer Publishing Company

Access to resources Recommend Favorite

Anti-CD20 Monoclonal Antibody (Rituximab) and Cidofovir as Successful Treatment of an EBV-Associated Lymphoma with CNS Involvement

By  

Oncology Research and Treatment, Vol. 24, Iss. 5, 2001-10 ,pp. : 491-494

Karger

Access to resources Recommend Favorite

The combination of milatuzumab, a humanized anti‐CD74 antibody, and veltuzumab, a humanized anti‐CD20 antibody, demonstrates activity in patients with relapsed and refractory B‐cell non‐Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 5, 2015-06 ,pp. : 701-710

John Wiley & Sons Inc

Access to resources Recommend Favorite

CD20‐negative diffuse large B‐cell lymphoma presenting with lactic acidosis

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 3, 2015-03 ,pp. : E49-E50

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the Literature

By  

Oncology Research and Treatment, Vol. 26, Iss. 4, 2003-09 ,pp. : 351-354

Karger

Access to resources Recommend Favorite